The Conversation (0)
February 21, 2023
Nirvana Life Sciences Inc., (CSE:NIRV) ("Nirvana" or the "Company") a Canadian based life sciences company aimed at developing non-addictive chronic pain and addiction treatment products announces that Mr. Chris Hoffmeister has resigned from the Company's Board of Directors. The Company thanks Mr. Hoffmeister for his service over the last 4 years.
About Nirvana Life Sciences
Nirvana Life Sciences Inc. (CSE:NIRV) is an innovator in the emerging Psychedelic space. At Nirvana, we believe that psylocibin derived medicines can play a leading role in reducing the impacts of the opioids crisis and build healthier communities.
For more information visit https://nirvanalifescience.com/
For further information: Bruce Clark, CEO info@nirvanalifescience.com Phone: 604-401-8100
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
NIRV:CC
21 November 2022
Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction
Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic and other natural based medicines, including non-addictive chronic pain and relapse preventing pharmaceutical medicines, is pleased to report that it... Keep Reading...
09 November 2022
Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors
Nirvana Life Sciences Inc.(CSE: NIRV) (Nirvana or the "Company") , a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors.Mr.... Keep Reading...
22 September 2022
Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives
Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to report filing of a patent for D7-h. Nirvana... Keep Reading...
07 September 2022
Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds
Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing pharmaceutical medicines and formulations to be used in trauma work,... Keep Reading...
06 July 2022
Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs
Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to announce it has acquired an exclusive... Keep Reading...
16 September
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto
lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
30 July
Psychedelics Market Update: H1 2025 in Review
The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
08 May
US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025
When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
03 March
Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia
Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia.... Keep Reading...
18 February
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...
23 January
Psychedelics Market Forecast: Top Trends for Psychedelics in 2025
The psychedelics investment landscape enters 2025 on a complex path marked by both progress and setbacks. While the US Food and Drug Association (FDA) continues to support research into the therapeutic potential of psychedelics, translating promising findings into approved treatments and... Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00